"Now that we have proven the feasibility on the bench of CO-oximetry in a unit-use device configuration with bovine blood, we anticipate an additional major milestone by December this year to bring it all together into a more advanced Proof-Of-Concept prototype that demonstrates the ability to package the technology into a hand-held form factor with enterprise cloud connectivity.", said Lahav Gil, CEO of Relay Medical Corp
|